.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own best biopharma pick for 2025 as well as ranked yet another 9 labels in the area as obese. The expenditure banking company said in a note that it continues to strongly believe “diabesity is readied to come to be.